Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3332052 | Hematology/Oncology Clinics of North America | 2008 | 14 Pages |
Abstract
Highly aggressive lymphomas are relatively uncommon in adults, comprising approximately 4% to 5% of all non-Hodgkin lymphomas in the United States and Western Europe. The designation of “highly aggressive” is generally restricted to precursor T-cell and B-cell lymphoblastic lymphoma/leukemia and Burkitt's lymphoma/leukemia. Treatment strategies for lymphoblastic lymphoma and Burkitt's lymphoma include complex, highly intensive combination chemotherapy regimens, which may be curative. As with other subtypes of NHL, emerging data from gene-expression profiling and related techniques are helping to define these entities more precisely and identify potential new rational therapeutic targets.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
John W. Sweetenham,